Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 0.84 |
| ▸ | PTGDR | Q13258 | 14/20 | 0.77 |
| ▸ | TBXA2R | P21731 | 8/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | CCKAR | P32238 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2522367 | 0.92 | PTGDR2 (1.00) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL2516080 | 0.92 | PTGDR2 (1.00) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL503112 | 0.92 | PTGDR2 (1.00) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL2779177 | 0.87 | PTGDR2 (0.84) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL16558831 | 0.87 | PTGDR2 (1.00) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL2516084 | 0.85 | PTGDR2 (0.81) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL9988986 | 0.83 | PTGDR2 (0.80) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL2778606 | 0.83 | PTGDR2 (0.84) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL2515554 | 0.83 | PTGDR2 (0.84) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 | |
| SCHEMBL2516999 | 0.83 | PTGDR2 (0.84) | PTGDR2PTGDRTBXA2RCYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301168-A1 | CYCLOALKANE[B]AZAINDOLE ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-08 | — | — | US | claimed |
| US-8034826-B2 | Cycloalkane[B]azaindole antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2011-10-11 | — | — | US | claimed |
| US-20100113503-A1 | CYCLOALKANE[B]AZAINDOLE ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | claimed |
| US-20110301168-A1 | CYCLOALKANE[B]AZAINDOLE ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-8034826-B2 | Cycloalkane[B]azaindole antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2011-10-11 | — | — | US | disclosed |
| US-20100113503-A1 | CYCLOALKANE[B]AZAINDOLE ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301168-A1 | CYCLOALKANE[B]AZAINDOLE ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885PTGDR 1/4885TBXA2R 6/4885 |
| US-20100113503-A1 | CYCLOALKANE[B]AZAINDOLE ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885PTGDR 1/4885TBXA2R 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.